The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Results of a phase 2 study of a novel DLL4-VEGF, a bispecific antibody, tovecimig (CTX-009), as a monotherapy in patients with refractory metastatic colorectal cancer (COMPANION-003).
 
Minal Barve
Employment - Texas Oncology
Stock and Other Ownership Interests - Texas Oncology
Research Funding - SCRI at Mary Crowley Cancer Research
 
Patrick Boland
Consulting or Advisory Role - Abbvie; BeiGene; Bristol Myers Squibb Foundation; Incyte; Incyte; Taiho Oncology
Research Funding - Caris Life Sciences (Inst); Compass Therapeutics (Inst); MEI Pharma (Inst); Merck (Inst); Processa Pharmaceuticals (Inst)
 
Fadi Kayali
No Relationships to Disclose
 
Sameh Mikhail
Honoraria - Jazz Pharmaceuticals
Consulting or Advisory Role - BeiGene; Ipsen; medical insights bioanalytics; Perthera
Speakers' Bureau - Jazz Pharmaceuticals
 
Kris Sachsenmeier
Employment - Compass Therapeutics; Takeda
Stock and Other Ownership Interests - Compass Therapeutics
Patents, Royalties, Other Intellectual Property - Patent pending for a cancer diagnostic.
Travel, Accommodations, Expenses - Compass Therapeutics
(OPTIONAL) Uncompensated Relationships - BreakBio
 
Sarah Pilgrim
Employment - Compass Therapeutics
Stock and Other Ownership Interests - Compass Therapeutics
 
Minori Rosales
Employment - The Compass Therapeutics
Stock and Other Ownership Interests - The Compass Therapeutics
 
Meredith Pelster
Honoraria - Castle Biosciences (I)
Consulting or Advisory Role - Arcus Biosciences (Inst); AstraZeneca (Inst); Curio Science (Inst); CytomX Therapeutics (Inst); Elevation Oncology (Inst); EMD Serono (Inst); Ipsen (Inst); Jazz Pharmaceuticals (Inst); Kura Oncology (Inst); Pfizer (Inst); Takeda (Inst)
Research Funding - 1200 Pharma (Inst); Abbvie (Inst); Actuate Therapeutics (Inst); Affini-T Therapeutics (Inst); Agenus (Inst); Arcus Biosciences (Inst); Artios (Inst); Astellas Pharma (Inst); BeiGene (Inst); BioNTech (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Codiak Biosciences (Inst); Compass Therapeutics (Inst); CytomX Therapeutics (Inst); Eisai (Inst); Elevation Oncology (Inst); Elicio Therapeutics (Inst); Exelixis (Inst); Fate Therapeutics (Inst); Fog Pharmaceuticals (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); HiberCell (Inst); Immune-Onc Therapeutics (Inst); IMPAC Medical Systems (Inst); Jazz Pharmaceuticals (Inst); Kura Oncology (Inst); Leap Therapeutics (Inst); Neogene (Inst); Novartis (Inst); OncXerna Therapeutics (Inst); Panbela Therapeutics (Inst); Revolution Medicines (Inst); Roche (Inst); Seagen (Inst); SQZ Biotechnology (Inst); Surface Oncology (Inst); Tachyon Therapeutics (Inst); Takeda (Inst); Translational Genomics Research Institute (Inst); TransThera Sciences (Nanjing), Inc. (Inst); ZielBio (Inst)